Demyelinating Diseases
|
0.010 |
Biomarker
|
group |
BEFREE |
The GPR17 receptor is an enigmatic receptor and an interesting therapeutic target in a variety of brain disorders and demyelinating diseases such as multiple sclerosis, stroke, schizophrenia, and depression.
|
30640576 |
2019 |
Multiple Sclerosis
|
0.030 |
Biomarker
|
disease |
BEFREE |
The GPR17 receptor is an enigmatic receptor and an interesting therapeutic target in a variety of brain disorders and demyelinating diseases such as multiple sclerosis, stroke, schizophrenia, and depression.
|
30640576 |
2019 |
Cerebrovascular accident
|
0.040 |
Biomarker
|
group |
BEFREE |
The GPR17 receptor is an enigmatic receptor and an interesting therapeutic target in a variety of brain disorders and demyelinating diseases such as multiple sclerosis, stroke, schizophrenia, and depression.
|
30640576 |
2019 |
Schizophrenia
|
0.010 |
Biomarker
|
disease |
BEFREE |
The GPR17 receptor is an enigmatic receptor and an interesting therapeutic target in a variety of brain disorders and demyelinating diseases such as multiple sclerosis, stroke, schizophrenia, and depression.
|
30640576 |
2019 |
Mental Depression
|
0.010 |
Biomarker
|
disease |
BEFREE |
The GPR17 receptor is an enigmatic receptor and an interesting therapeutic target in a variety of brain disorders and demyelinating diseases such as multiple sclerosis, stroke, schizophrenia, and depression.
|
30640576 |
2019 |
Depressive disorder
|
0.010 |
Biomarker
|
disease |
BEFREE |
The GPR17 receptor is an enigmatic receptor and an interesting therapeutic target in a variety of brain disorders and demyelinating diseases such as multiple sclerosis, stroke, schizophrenia, and depression.
|
30640576 |
2019 |
Depressed mood
|
0.010 |
Biomarker
|
phenotype |
BEFREE |
The GPR17 receptor is an enigmatic receptor and an interesting therapeutic target in a variety of brain disorders and demyelinating diseases such as multiple sclerosis, stroke, schizophrenia, and depression.
|
30640576 |
2019 |
CNS disorder
|
0.010 |
Biomarker
|
group |
BEFREE |
The absence of Gpr17 enhances remyelination is correlate with the activated Erk1/2 (phospho-Erk1/2).Being a membrane receptor, Gpr17 represents an ideal druggable target to be exploited for innovative regenerative approaches to acute and chronic CNS diseases.
|
29540737 |
2018 |
Fascioliasis
|
0.010 |
Biomarker
|
disease |
BEFREE |
The experimental design reproduces the usual reinfection/chronicity conditions in human fascioliasis endemic areas and included Fasciola hepatica primo-infected Wistar rats (PI) and rats reinfected at 8 weeks (R8), and at 12 weeks (R12), and negative control rats.
|
28362822 |
2017 |
Failure to Thrive
|
0.010 |
Biomarker
|
disease |
BEFREE |
The four previously reported cases of r(12) support the theory of a general ring phenotype which is manifested independently of the specific autosome involved and which is characterized by growth failure, moderate mental retardation, and lack of other major phenotypic anomalies.
|
3354616 |
1988 |
Growth failure
|
0.010 |
Biomarker
|
phenotype |
BEFREE |
The four previously reported cases of r(12) support the theory of a general ring phenotype which is manifested independently of the specific autosome involved and which is characterized by growth failure, moderate mental retardation, and lack of other major phenotypic anomalies.
|
3354616 |
1988 |
Nasal Polyps
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
The increased expression of GPR17 in nasal polyps and the differential expression between eosinophilic and non-eosinophilic CRSwNP subsets suggest that these subsets may have distinct pathogenic mechanisms.
|
29161055 |
2018 |
Neoplasms
|
0.020 |
GeneticVariation
|
group |
BEFREE |
The karyotype of the primary tumor was 46,X,del(X)(p?11p?22), der(12)(12pter→12q?22::12q?15→q?22::16p11→16pter),-16,+r(12).
|
25176350 |
2014 |
Degenerative polyarthritis
|
0.010 |
Biomarker
|
disease |
BEFREE |
The methylation of genes ADCY4, ADCY6 and GPR17, as well as the gonadotropin-releasing hormone signaling pathway, was newly found to be potentially associated with OA.They may be novel OA markers.
|
27810435 |
2016 |
Middle Cerebral Artery Occlusion
|
0.030 |
Biomarker
|
disease |
BEFREE |
The rats were divided into eight groups randomly: (1) sham-operated group, (2) ischemia group, (3-5) ischemia-reperfusion (middle cerebral artery occlusion and reperfusion (MCAO/R) 12 h, 48 h, and 7 days) and 0.9% saline groups, (6-8) ischemia-reperfusion (MCAO/R 12 h, 48 h, and 7 days) and Ang-1 groups.
|
21710361 |
2012 |
Anterior Cerebral Circulation Infarction
|
0.300 |
Therapeutic
|
phenotype |
CTD_human |
The recently identified P2Y-like receptor GPR17 is a sensor of brain damage and a new target for brain repair.
|
18974869 |
2008 |
Anterior Circulation Brain Infarction
|
0.300 |
Therapeutic
|
phenotype |
CTD_human |
The recently identified P2Y-like receptor GPR17 is a sensor of brain damage and a new target for brain repair.
|
18974869 |
2008 |
Brain Infarction, Posterior Circulation
|
0.300 |
Therapeutic
|
phenotype |
CTD_human |
The recently identified P2Y-like receptor GPR17 is a sensor of brain damage and a new target for brain repair.
|
18974869 |
2008 |
Venous Infarction, Brain
|
0.300 |
Therapeutic
|
phenotype |
CTD_human |
The recently identified P2Y-like receptor GPR17 is a sensor of brain damage and a new target for brain repair.
|
18974869 |
2008 |
Malignant neoplasm of breast
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
There was a significant genetic correlation between ovarian and breast cancer (R12 = .484).
|
2491011 |
1989 |
Breast Carcinoma
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
There was a significant genetic correlation between ovarian and breast cancer (R12 = .484).
|
2491011 |
1989 |
Congenital chromosomal disease
|
0.010 |
Biomarker
|
group |
BEFREE |
There were only single published cases of most small rings but there were three r(8) cases, two r(1) cases, two r(12) cases, and two r(20) cases, uncomplicated by the presence of other chromosome abnormalities.
|
7802042 |
1994 |
Hormone refractory prostate cancer
|
0.010 |
Biomarker
|
disease |
BEFREE |
These data suggest that compound (R)-12 is a promising lead compound for the development of a new class of therapeutics for the treatment of CRPC.
|
29758518 |
2018 |
Heart failure
|
0.010 |
Biomarker
|
disease |
BEFREE |
These pilot results suggest cardiac-specific gene therapy using BB-R12 may reverse cardiac dysfunction by myosin activation in a large-animal heart failure model with no observed safety concerns.
|
25876005 |
2015 |
Congestive heart failure
|
0.010 |
Biomarker
|
disease |
BEFREE |
These pilot results suggest cardiac-specific gene therapy using BB-R12 may reverse cardiac dysfunction by myosin activation in a large-animal heart failure model with no observed safety concerns.
|
25876005 |
2015 |